CTLA4 and cancer: Indeed, it has been shown that a cocktail of IDO1 inhibitors and immunotherapeutic drugs, including agents targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4) or PD-1, displays a synergistic effect in combating cancer [48,49].